Voyager Therapeutics’ (VYGR) Hold Rating Reiterated at Chardan Capital

Chardan Capital restated their hold rating on shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) in a report published on Sunday morning.

VYGR has been the subject of a number of other research reports. Zacks Investment Research lowered Voyager Therapeutics from a hold rating to a sell rating in a report on Thursday, July 13th. Stifel Nicolaus started coverage on Voyager Therapeutics in a report on Friday, July 28th. They issued a buy rating and a $20.00 target price for the company. ValuEngine upgraded Voyager Therapeutics from a strong sell rating to a sell rating in a report on Friday, September 1st. Cowen and Company restated a buy rating on shares of Voyager Therapeutics in a report on Tuesday, August 8th. Finally, BidaskClub upgraded Voyager Therapeutics from a strong sell rating to a sell rating in a report on Thursday, July 13th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $23.43.

Voyager Therapeutics (NASDAQ:VYGR) opened at 14.32 on Friday. The firm’s market capitalization is $385.25 million. Voyager Therapeutics has a 12-month low of $8.10 and a 12-month high of $18.25. The stock has a 50 day moving average price of $9.57 and a 200-day moving average price of $10.30.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). The business had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $3.27 million. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. On average, equities research analysts forecast that Voyager Therapeutics will post ($2.84) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2017/09/13/voyager-therapeutics-vygr-hold-rating-reiterated-at-chardan-capital.html.

In other news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total value of $54,900.00. Following the transaction, the insider now directly owns 17,157 shares of the company’s stock, valued at $171,570. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 6.00% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. increased its stake in shares of Voyager Therapeutics by 0.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 29,035 shares of the company’s stock worth $261,000 after acquiring an additional 114 shares during the last quarter. Fiduciary Trust Co. increased its stake in shares of Voyager Therapeutics by 0.4% in the second quarter. Fiduciary Trust Co. now owns 109,034 shares of the company’s stock worth $977,000 after acquiring an additional 473 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Voyager Therapeutics by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after acquiring an additional 1,399 shares during the last quarter. Teachers Advisors LLC increased its stake in shares of Voyager Therapeutics by 9.8% in the fourth quarter. Teachers Advisors LLC now owns 20,604 shares of the company’s stock worth $262,000 after acquiring an additional 1,847 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Voyager Therapeutics by 8.4% in the second quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock worth $231,000 after acquiring an additional 2,000 shares during the last quarter. 40.70% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply